<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0186-4866</journal-id>
<journal-title><![CDATA[Medicina interna de México]]></journal-title>
<abbrev-journal-title><![CDATA[Med. interna Méx.]]></abbrev-journal-title>
<issn>0186-4866</issn>
<publisher>
<publisher-name><![CDATA[Edición y Farmacia S.A. de C.V.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0186-48662018000100011</article-id>
<article-id pub-id-type="doi">10.24245/mim.v34i1.1429</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Actualización en la prescripción de fluoroquinolonas]]></article-title>
<article-title xml:lang="en"><![CDATA[Update on the prescription of fluoroquinolones.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carrillo-Alduenda]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Flores-Murrieta]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Alcocer]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Politécnico Nacional Escuela Superior de Medicina ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Centro de investigación Clínica Paracelsus  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2018</year>
</pub-date>
<volume>34</volume>
<numero>1</numero>
<fpage>89</fpage>
<lpage>105</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0186-48662018000100011&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0186-48662018000100011&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0186-48662018000100011&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: Las quinolonas o fluoroquinolonas son un grupo de antibióticos frecuentemente prescritos y de amplio espectro que actúan inhibiendo a las enzimas encargadas de la replicación, transcripción, reparación y recombinación del ADN bacteriano. El objetivo de este artículo es presentar una revisión sistemática de los antecedentes, farmacocinética y actividad microbiológica de las tres fluoroquinolonas más representativas en nuestro medio (ciprofloxacino, levofloxacino y moxifloxacino) en sus tres indicaciones actualmente autorizadas: infecciones de vías respiratorias inferiores, de vías urinarias, de piel y tejidos blandos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Quinolones or fluoroquinolones are a group of commonly prescribed and broad-spectrum antibiotics drugs that act by inhibiting the enzymes responsible for the bacterial DNA replication, transcription, repair and recombination. The aim of this article is to present a systematic review of the three most representative fluoroquinolones in our country (ciprofloxacin, levofloxacin and moxifloxacin) in their three authorized indications: lower respiratory tract infections, urinary tract infections, skin and soft tissues infections.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Fluoroquinolonas]]></kwd>
<kwd lng="es"><![CDATA[quinolonas]]></kwd>
<kwd lng="es"><![CDATA[ciprofloxacino]]></kwd>
<kwd lng="es"><![CDATA[levofloxacino]]></kwd>
<kwd lng="en"><![CDATA[Fluoroquinolones]]></kwd>
<kwd lng="en"><![CDATA[Quinolones]]></kwd>
<kwd lng="en"><![CDATA[Ciprofloxacin]]></kwd>
<kwd lng="en"><![CDATA[Levofloxacin]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oliphant]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[GM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quinolones: A comprehensive review]]></article-title>
<source><![CDATA[Am Fam Physician]]></source>
<year>2002</year>
<volume>65</volume>
<page-range>455-64</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scheld]]></surname>
<given-names><![CDATA[WM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Maintaining fluoroquinolone class efficacy: Review of influencing factors]]></article-title>
<source><![CDATA[Emerg Infect Dis]]></source>
<year>2003</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<collab>Essential Medicines and Health Products Information Portal Ginebra, Organización Mundial de la Salud</collab>
<source><![CDATA[]]></source>
<year>1999</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<collab>Gatifloxacin (marketed as Tequin) Information</collab>
<collab>Estados Unidos de América, Food and Drug Administration (FDA)</collab>
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<collab>Consulta de registros sanitarios México, Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS)</collab>
<source><![CDATA[]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galan Herrera]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Poo]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Rosales Sánchez]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bioavailability of two oral formulations of a single dose of levofloxacin 500 mg: An open-label, randomized, two-period crossover comparison in healthy Mexican volunteers]]></article-title>
<source><![CDATA[Clin Ther]]></source>
<year>2009</year>
<volume>31</volume>
<page-range>1796-803</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lubasch]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Keller]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Borner]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2000</year>
<volume>44</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2600-3</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lomaestro]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Bailie]]></surname>
<given-names><![CDATA[GR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Absorption interactions with fluoroquinolones]]></article-title>
<source><![CDATA[Drug Saf]]></source>
<year>1995</year>
<volume>12</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>314-33</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mendoza Tamayo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rosete Reyes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Medina Santillán]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bioavailability of two tablet formulations of a single dose of moxifloxacin 400 mg: An open-label, randomized, two-period crossover comparison in healthy Mexican adult volunteers]]></article-title>
<source><![CDATA[J Bioequiv Availab]]></source>
<year>2014</year>
<volume>6</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>197-201</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhanel]]></surname>
<given-names><![CDATA[GG]]></given-names>
</name>
<name>
<surname><![CDATA[Walkty]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vercaigne]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The new fluoroquinolones: A critical review]]></article-title>
<source><![CDATA[Can J Infect Dis]]></source>
<year>1999</year>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>207-38</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lettieri]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Blum]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>1996</year>
<volume>38</volume>
<page-range>103-16</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="">
<collab>Levaquin, multiple routes and forms. Estados Unidos de América, Food and Drug Administration (FDA)</collab>
<source><![CDATA[]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhanel]]></surname>
<given-names><![CDATA[GG]]></given-names>
</name>
<name>
<surname><![CDATA[Ennis]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Vercaigne]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A critical review of the fluoroquinolones focus on respiratory tract infections]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2002</year>
<volume>62</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>13-59</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="">
<collab>Cipro tablets. (Internet) Estados Unidos de América, Food and Drug Administration (FDA)</collab>
<source><![CDATA[]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<collab>Avelox, IV, Tablets 400 mg. Estados Unidos de América, Food and Drug Administration (FDA)</collab>
<source><![CDATA[]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="">
<collab>Guidelines on Urological infections European Association of Urology</collab>
<source><![CDATA[]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="">
<collab>The Johns Hopkins Hospital</collab>
<source><![CDATA[Antibiotic Guidelines]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ortega-Romeroa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sorianoa]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectos adversos de las fluoroquinolonas]]></article-title>
<source><![CDATA[Med Integr]]></source>
<year>2000</year>
<volume>36</volume>
<page-range>396-9</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kalil]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Metersky]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Klompas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2016</year>
<page-range>1-51</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<collab>Guía de Práctica Clínica Prevención</collab>
<source><![CDATA[Diagnóstico y Tratamiento de la Neumonía Adquirida en la Comunidad en Adultos]]></source>
<year>2009</year>
<volume>36</volume>
<publisher-name><![CDATA[Instituto Mexicano del Seguro Social]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Woodhead]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Blasi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ewig]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines for the management of adult lower respiratory tract infections]]></article-title>
<source><![CDATA[Clin Microbiol Infect]]></source>
<year>2011</year>
<volume>17</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>E1-E59</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="">
<collab>Guía de práctica clínica</collab>
<source><![CDATA[Diagnóstico y tratamiento de la enfermedad pulmonar obstructiva. México: Secretaría de Salud]]></source>
<year>2009</year>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Postma]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[van Werkhoven]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[van Elden]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibiotic treatment strategies for community-acquired pneumonia in adults]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>372</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1312-23</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moss]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Finch]]></surname>
<given-names><![CDATA[RG.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults]]></article-title>
<source><![CDATA[Thorax]]></source>
<year>2000</year>
<volume>55</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>83-5</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Nichol]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Hoban]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Zhanel]]></surname>
<given-names><![CDATA[GG.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2002</year>
<volume>49</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>893-5</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Atwood]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit a proposed solution for indiscriminate antibiotic prescription]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>2000</year>
<volume>162</volume>
<page-range>505-11</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gutiérrez-Castrellón]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz-García]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[de Colsa-Ranero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of ciprofloxacin treatment in urinary tract infections (UTIs) in adults: a systematic review with meta-analysis]]></article-title>
<source><![CDATA[Gac Méd Méx]]></source>
<year>2015</year>
<volume>151</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>225-44</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dielubanza]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Schaeffer]]></surname>
<given-names><![CDATA[AJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Urinary tract infections in women]]></article-title>
<source><![CDATA[Med Clin North Am]]></source>
<year>2011</year>
<volume>95</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>27-41</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Drekonja]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[JR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Urinary tract infections]]></article-title>
<source><![CDATA[Prim Care]]></source>
<year>2008</year>
<volume>35</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>345-67</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bisno]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Chambers]]></surname>
<given-names><![CDATA[HF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 Update by the Infectious Diseases Society of America]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2014</year>
<volume>59</volume>
<page-range>e10-52</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Liceaga]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Arrioja]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía clínica basada en evidencia para el manejo del pie diabético]]></article-title>
<source><![CDATA[Med Int Méx]]></source>
<year>2009</year>
<volume>25</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>481-526</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Majcher-Peszynska]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sass]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schipper]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort]]></article-title>
<source><![CDATA[Eur J Clin Pharmacol]]></source>
<year>2011</year>
<volume>67</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>135-42</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bradley]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Jackson]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical report, The use of systemic and topical fluoroquinolones]]></article-title>
<source><![CDATA[Pediatrics]]></source>
<year>2011</year>
<volume>128</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>e1034-45</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<collab>Grupo de trabajo sobre niveles de evidencia del OCEBM*</collab>
<article-title xml:lang=""><![CDATA[Niveles de evidencia 2011 de Oxford (The Oxford 2011 Levels of Evidence)]]></article-title>
<source><![CDATA[Oxford Centre for Evidence-Based Medicine]]></source>
<year></year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
